A phase I/II clinical study of F-1515 in combination with F-1520 in patients with somatostatin receptor positive, progressive midgut carcinoids and other neuroendocrine tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs F-1520 (Primary) ; Lutetium-(177Lu)-oxodotreotide (Primary)
Indications Carcinoid tumour; Gastrointestinal cancer; Lung cancer; Neuroendocrine tumours; Pancreatic cancer
Focus Pharmacokinetics; Therapeutic Use
Sponsors FUJIFILM Pharma; FUJIFILM Toyama Chemical

23 Jun 2021 According to FUJIFILM Toyama Chemical media release, the company has confirmed the drugs efficacy and safety in Japanese patients through a phase I clinical study and a phase I/II clinical study, and filed an application for marketing authorization approval in 2020
18 Jun 2018 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com